Psychiatric News (11/20) reports, “A subset of individuals 65 years or older with treatment-resistant depression who took a new oral antidepressant plus intranasal esketamine showed greater improvement of symptoms than those who took an antidepressant and intranasal placebo,” research indicated. The 138-patient study, however, revealed that “the overall difference between the esketamine and placebo groups in symptom score reduction was not statistically significant, indicating a need for further research.” The findings were published online Oct. 17 in the American Journal of Geriatric Psychiatry.(SOURCE: APA Headlines)